Klinik Ottakring, 2.Medizinische Abteilung mit Pneumologie, Karl Landsteiner Institut für Lungenforschung und Pneumologische Onkologie
Ansprechpartner: OA Dr. Klaus Kirchbacher klaus.kirchbacher@gesundheitsverbund.at
Landsteiner Lung Cancer Research Platform (LALUCA) – A prospective analysis of Lung Cancer Diagnosis and Management in Clinical Practice
Patientenpopulation: alle Patientinnen und Patientin mit Lungenkrebs
Zeitrahmen: seit 2020, open end
Universitätsklinikum Krems, Abteilung für Pneumologie
NSCLC early stage
CODEBREAK 202: Phase 3, First line, Pembro + Platin-Dublette (SoC) versus Sotorasib + Platin-Dublette bei Patienten mit KRAS G12C und PDL-1 <1%
Ansprechpartner: OA Dr. Hackner Klaus, klaus.hackner@krems.lknoe.at
DELLphi 304: AMG 757- Tarlatamab- 20210004 : A Randomized, Open-label, Phase 3 Study of Tarlatamab Compared With Standard of Care in Subjects with Relapsed Small Cell Lung Cancer After Platinum-based First Line Chemotherapy
Ansprechpartner: OA Dr. Sabin Handzhiev, sabin.handzhiev@krems.lknoe.at
1st line ES-SCLC
SPACE: Single-Arm Phase II-Study in Patients with extensive stage small-cell lung cancer (ES-SCLC) with Poor Performance Status receiving Atezolizumab-Carboplatin-Etoposide
Start: Okt. 2020
Ansprechpartner: OA Dr. Klaus Hackner, klaus.hackner@krems.lknoe.at
SCLC relapsed, refractory
AMG 757 (DeLphi-301): A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of AMG 757
in Subjects with Relapsed/Refractory Small Cell Lung Cancer After Two or More Prior Lines of Treatment
Start: Feb. 2022
Ansprechpartner: OA Dr. Sabin Handzhiev, sabin.handzhiev@krems.lknoe.at
Kepler Universitätsklinikum, Universitätsklinik für Innere Medizin 4 – Pneumologie
Ansprechpartnerin: OÄ Dr. Romana Wass, PhD romana.wass@kepleruniklinikum.at
NSCLC early stage
KEYNOTE-867: A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Participants With Unresected Stages I or II Non Small Cell Lung Cancer (NSCLC)
https://clinicaltrials.gov/ct2/show/NCT03924869
SKYSCRAPER 03: A Phase III, Open-Label, Randomized Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Patients With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer Who Have Not Progressed After Concurrent Platinum-Based Chemoradiation
https://clinicaltrials.gov/ct2/show/NCT04513925
1st line ES-SCLC
Klinikum Klagenfurt, Abteilung für Lungenkrankheiten
Ansprechpartner: Prim. Dr. Markus Rauter, Markus.Rauter@kabeg.at
NSCLC
ImReal MO40653: A non-interventional, multi-centre, multiple cohort study to investigate the outcomes and safety of atezolizumab under real-life conditions in patients treated in routine clinical practice.
KontRASt-06: An open-label phase II trial evaluating the activity and safety ofJDQ443 single-agent as first-line treatment for patients with locally advanced or metastatic KRAS G12C-mutated non-small cell lung cancer with a PDL1 expression < 1% or a PD-L1 expression < 1% and an STK11 co-mutation.
https://classic.clinicaltrials.gov/ct2/show/NCT05445843
Sotorasib AMGEN: A Phase 3, Multicenter, Randomized, Open-label Study Evaluating Efficacy of Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Subjects with Stage IV or advanced Stage IIIB/C nonsquamous Non–Small Cell Lung Cancers, Negative for PD-L1, and positive for KRAS p.G12C (CodeBreaK 202)
https://classic.clinicaltrials.gov/ct2/show/NCT05920356
Tropion Lung 08: A Randomized, Open-label, Phase 3 Trial of Datopotamab Deruxtecan (Dato-DXd) Plus Pembrolizumab vs Pembrolizumab alone in Treatment-naive Subjects with Advanced or Metastatic PD-L1 High (TPS >50%) Non-small Gell Lung Cancer without actionable genomic Alterations
https://classic.clinicaltrials.gov/ct2/show/NCT05215340
Tropion Lung 07: A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab, with or Without Platinum Chemotherapy, in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS<50% Non-squamous Non-small Cell Lung Cancer without actionable genomic Alterations (TROPION-LUNG07)”
https://classic.clinicaltrials.gov/ct2/show/NCT05555732
GS-US-626-6216 – Star-121: A Randomized, Open-Label, Phase 3 Study to evaluate Zimberelimab and Domvanalimab in combination with Chemotherapy versus Pembrolizumab with Chemotherapy for the First-Line Treatment of Patients With Metastatic Non–Small Cell Lung Cancer with No epidermal growth factor receptor or anaplastic Lymphoma kinase genomic tumor Aberrations
https://classic.clinicaltrials.gov/ct2/show/NCT05502237
Mirati Krystal7: A Phase 2 Trial of MRTX849 Adagrasib Monotherapy and in Combination with Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination with Pembrolizumab versus Pembrolizumab plus Chemotherapy in Patients with Advanced Non-Small KRAS G12C Mutations
https://classic.clinicaltrials.gov/ct2/show/NCT04613596
MO42720 – Origama: Interventional platform Study investigating the impact of digital health solutions on health outcomes and health-care resource utilization in participants receiving systemic treatment in clinical practice (ORIGAMA)
ALK positive
Brigatinib 5007 – PASS: A Cohort Study to Describe the Occurrence of Early-Onset Pulmonary Events in Patients with Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Treated with Brigatinib: A Post-
MO42122 ReAlec: A multicenter noninterventional cohort study to evaluate the real world clinical managements and outcomes of patients diagnosed with ALK positive advanced NSCLC treated with Alectinib (Realec)
1st line ES-SCLC
Medizinische Universität Graz, Klinische Abteilung für Onkologie, in Zusammenarbeit mit LKH Hochsteiermark
Ansprechpartnerin: Priv.-Doz. Dr. Angelika Terbuch, angelika.terbuch@medunigraz.at
SCLC
Natters Innsbruck Thoracic Oncology Group (NITOG)
Ansprechpartner: Priv.-Doz. Dr. Andreas Pircher, andreas.pircher@i-med.ac.at
NSCLC early stage
INN-WOP1, Phase II: Neoadjuvante Window-Of-Opportunity-Studie zur Kurzzeittherapie mit Pembrolizumab/Lenvatinib vor OP eines NSCLC in frühen Stadien. Postoperativ Pembrolizumab für 1 Jahr. Akademische, monozentrische Studie. Nach erfolgtem Amendment können Patient*innen sowohl vor als auch nach erfolgter histologischer Diagnosesicherung eingeschlossen werden.
MK2870-019: Adjuvant: Pembrolizumab + MK2870 (TROP2-ADC) vs. Pembrolizumab
NSCLC metastatic
TROPION-Lung10: Datopotamab-Deruxtecan (TROP2-ADC) + Rilvegostimig (PD-1 und TIGIT bispecific AK) vs. Rilvegostomig vs. Pemrolizumab
https://classic.clinicaltrials.gov/ct2/show/NCT06357533
LUNAR-2: Phase III Tumor Treating fields (TTF) + Pembrolizumab/Platin-doublet vs. Pembrolizumab/Platin-doublet
https://classic.clinicaltrials.gov/ct2/show/NCT06216301
LUNAR-4: Phase II Tumor Treating fields (TTF) + Pembrolizumab
AMG20230167: Phase Ib/II AMG193 (methylthioadenosine (MTA)- cooperative protein arginine methyltransferase 5 (PRMT5) inhibitor) + Standard of Care
Metastatic, heavy pretreated
BI1456-0001: Phase I BI 1831169 (onkolytischer RNA Virus) + Checkpoint Inhibitor
https://clinicaltrials.gov/study/NCT05155332
PALINDROM: APN401-104 (PBMC basierte Leukozyten Immuntherapie)
SOUND: Comprehensive genomic tumour profiling including liquid biopsy